Acute effects of levosimendan and dobutamine on QRS duration in patients with heart failure;Efeitos agudos de levosimendana e dobutamina na duração do QRS em pacientes com insuficiência cardíaca

Arquivos Brasileiros de Cardiologia

Volumn 95, Issue 6, 2010, Pages 738-742

  Yontar, Osman Can ^a   Yilmaz, Mehmet Birhan ^a   Yalta, Kenan ^a   Erdem, Alim ^a   Tandogan, Izzet ^a  

^a CUMHURIYET UNIVERSITY   (Turkey)

Author keywords

Cardiotonic agents; Dobutamine adverses effects; Heart failure; Levosimendan

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; FUROSEMIDE; LEVOSIMENDAN; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CARDIAC PATIENT; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CELL; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; QRS COMPLEX; RANDOMIZED CONTROLLED TRIAL; SINUS RHYTHM;

AGED; CARDIOTONIC AGENTS; CHI-SQUARE DISTRIBUTION; DOBUTAMINE; FEMALE; HEART CONDUCTION SYSTEM; HEART FAILURE; HUMANS; HYDRAZONES; MALE; MUSCLE CONTRACTION; PYRIDAZINES; STATISTICS, NONPARAMETRIC;

EID: 79551586267     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2010005000143     Document Type: Article

References (14)

1. McBride B, White M. Levosimendan: implications for clinicians. J Clin Pharmacol. 2003; 43 (10): 1071-81.
2. Endoh M. The therapeutic potential of novel cardiotonic agents. Expert Opin Investig Drugs. 2003; 12 (5): 735-50. (Pubitemid 36644121)
3. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double blind study (RUSSLAN). Eur Heart J. 2002; 23 (18): 1422-32.
4. Cavusoglu Y, Tek M, Birdane A, Ata N, Demirustu C, Gorenek B, et al. Both levosimendan and dobutamine treatments result in significant reduction of NT-proBNP levels, but levosimendan has better and prolonged neurohormonal effects than dobutamine. Int J Cardiol. 2008; 127 (3): e188-91. (Pubitemid 351885120)
5. Tavares M, Andrade AC, Mebazaa A. Levosimendan use in several scenarios of acute heart failure. Arq Bras Cardiol. 2008; 90 (3): 231-5. (Pubitemid 351520767)
6. Iuliano S, Fisher SG, Karasik PE, Fletcher RD, Singh SN. Department of Veterans Affairs Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. QRS duration and mortality in patients with congestive heart failure. Am Heart J. 2002; 143 (6): 1085-91.
7. Shenkman HJ, Pampati V, Khandelwal AK, McKinnon J, Nori D, Kaatz S, et al. Congestive heart failure and QRS duration: establishing prognosis study. Chest. 2002; 122 (2): 528-34. (Pubitemid 35002131)
8. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. American Society of Echocardiography's Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr. 2006; 7 (2): 79-108.
9. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, et al. The epidemiology of heart failure. Eur Heart J. 1997; 18 (2): 208-25.
10. Bode-Schnurbus L, Böcker D, Block M, Gradaus R, Heinecke A, Breithardt G, et al. QRS duration: a simple marker for predicting cardiac mortality in ICD patients with heart failure. Heart. 2003; 89 (10): 1157-62. (Pubitemid 37164003)
11. Xiao HB, Roy C, Fujimoto S, Gibson DG. Natural history of abnormal conduction and its relation to prognosis in patients with dilated cardiomyopathy. Int J Cardiol. 1996; 53 (2): 163-70.
12. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al. SURVIVE Investigators. Levosimendan vs Dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA. 2007; 297 (17): 1883-91.
13. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000; 36 (6): 1903-12.
14. Bocchi EA, Bilas-Boas F, Moreira M, Barreto AC, Lage S, Albuquerque D, et al. e Grupo de estudos de insuficiencia cardiaca da Sociedade Brasileira de Cardiologia. Study BELIEF et al. Levosimendan in decompensated heart failure patients: efficacy in a Brazilian cohort. Results of the BELIEF study. Arq Bras Cardiol. 2008; 90 (3): 182-90.